3 stories mentioning SGMTUpdated 40d ago
Every FINWIRES story that references SGMT, newest first.
Sagimet Biosciences (SGMT) has joined the Russell 3000 and Russell 2000 indexes, effective Monday, as part of the 2026 Russell Indexes reconstitution, the company said on the same day.The company said it has capital in place to fund its programs through 2028, including a planned phase 3 trial of denifanstat in moderate to severe acne, expected in H2.Price: $7.20, Change: $+0.14, Percent Change: +1.91%
Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $7.93, Change: $-0.11, Percent Change: -1.31%
Sagimet Biosciences (SGMT) said Monday it has priced an underwritten offering of about 29.2 million shares at $6.00 each to raise about $175 million to help fund its clinical trial.Shares soared 43% as intraday trading volume catapulted to over 45.2 million from a daily average of about 516,000.Veradermics (MANE) said Monday part A of its phase 2/3 trial of VDPHL01 oral pill in males with mild-to-moderate pattern hair loss met all primary and all key secondary endpoints with "high" statistical significance.Shares surged 32%, with intraday trading volume of over 2.5 million from a daily average of roughly 446,000.Oruka Therapeutics (ORKA) jumped 16% after the company said Monday almost 64% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.More than 5.10 million shares traded intraday, compared with a daily average of about 760,000.Price: $8.36, Change: $+2.50, Percent Change: +42.58%
